Ra-226 Target Isotope Production via Segmented Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient methods and systems to produce medical isotopes, particularly Ac-225 and Pb-212, which are crucial for Targeted Alpha Therapy, but current production methods are limited and inefficient.
Innovation Solution
A method involving the irradiation of Ra-226 targets with charged particles or photons to produce Ac-225 and Ac-224, followed by chromatography and extraction chromatography using a resin with 18-crown-6 ether to separate and purify Pb-212, maximizing the co-production of Pb-212 while maintaining efficient Ac-225 production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Ra-226 targets are irradiated with protons to produce Ac-225, then Ac-225 is formed in the Ra-226 (p, 2n) Ac-225 nuclear reaction, but Pb-212 is produced as a by-product that requires additional separation steps
Solution Approach 1:
The separation process is divided into distinct stages: first separating actinium from radium using extraction chromatography with DGA resin, then separately separating lead from radium using extraction chromatography with Sr resin. This segmentation allows each separation step to be optimized independently for its specific separation task.
Solution Approach 2:
The patent introduces intermediate separation steps using specific resin materials (DGA resin for actinium/radium separation, Sr resin for lead/radium separation) that act as mediators to selectively separate the desired isotopes from the target material and from each other.
2Productivity
If irradiation energy is increased to produce more Ac-225, then the threshold energy for (p, 3n) reaction is reached leading to production of Ac-224, which decays to Ra-224
Solution Approach 1:
The patent extracts and removes the harmful by-products (Ac-224 and Ra-224) from the production stream through selective separation steps. The DGA resin column selectively retains actinium isotopes while allowing radium to pass through, and the Sr resin column selectively retains lead while allowing radium to pass through, thereby removing contaminants from the final Ac-225 product.
Solution Approach 2:
The patent converts the harmful by-product Ra-224 into a beneficial source of Pb-212 by allowing it to decay. The Ra-224 produced during Ac-225 production is not discarded but rather utilized to generate Pb-212, which is a valuable isotope for targeted alpha therapy, through its decay chain: Ra-224 → Rn-220 → Po-216 → Pb-212.
3Manufacturing precision
If multiple separation steps are applied to purify Ac-225 from Ra and progeny, then purity is improved, but processing time and complexity increase
Solution Approach 1:
The patent performs preliminary separation of actinium from radium immediately after irradiation using DGA resin, before the radium decays to produce significant amounts of lead. This timing optimizes the separation efficiency and reduces the total processing time required, as subsequent lead separation can be performed more efficiently when radium content is lower.
Solution Approach 2:
The patent changes the chemical parameters (acid concentration, flow rate, resin type) of the separation process to optimize both purity and time. Specific conditions such as using DGA resin in certain acid concentrations for actinium separation and Sr resin for lead separation are parameter-optimized to achieve high purity with minimal processing time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient production of Pb-212 as a by-product of Ac-225 production, enhancing the availability of isotopes for Targeted Alpha Therapy while minimizing contamination and optimizing processing efficiency.
Implementation Method 1
applying extraction chromatography using a resin having an 18-crown-6 ether or an equivalent of 18-crown-6 ether, as extractant in HNO3 and/or HCl for separating Pb from the remaining fraction containing radium
Implementation Method 2
applying chromatography for separating actinium from the remaining fraction containing radium
Implementation Method 3
irradiating a Ra-226 containing target with charged particles and/or photons for producing at least Ac-225 isotopes and Ac-224 isotopes
Data Source
AI summary
A method for producing Pb-212 and Ac-225 isotopes includes irradiating a Ra-226 containing target with charged particles and producing an irradiated target having at least Ac-225 isotope particles. Following irradiation and a cooling period, actinium isotopes are separated from a residual radium-containing fraction using chromatography. Subsequently, after an additional waiting period, lead isotopes are separated from the remaining radium fraction through extraction chromatography. The extraction process employs a resin containing an 18-crown-6 ether or an equivalent in a nitric acid (HNO3) and/or hydrochloric acid (HCl) medium to isolate Pb-212 and Ac-225 isotope particles.